Today, in America, a high school freshman studying science is as old as the last Food and Drug Administration (FDA) approved treatment for Alzheimer’s disease. Soon, this may change.
By the close of this year, the Indianapolis based Fortune 500 pharmaceutical company Lilly, whose products have included the anti-depressant Prozac and human insulin, will release the results of Expedition 3, a study testing a drug that targets amyloid in persons with mild stage dementia caused by Alzheimer’s disease. Its subjects are unique. They don’t simply have Alzheimer’s disease diagnosed by a careful history and exam. They have a brain scan showing amyloid accumulation.
